Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection

OBJECTIVES: Ridinilazole (SMT19969) is a narrow-spectrum, non-absorbable antimicrobial with activity against Clostridium difficile undergoing clinical trials. The purpose of this study was to assess the pharmacological activity of ridinilazole and assess the effects on cell morphology. METHODS: Anti...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Antimicrob Chemother
Huvudupphovsmän: Bassères, Eugénie, Endres, Bradley T., Khaleduzzaman, Mohammed, Miraftabi, Faranak, Alam, M. Jahangir, Vickers, Richard J., Garey, Kevin W.
Materialtyp: Artigo
Språk:Inglês
Publicerad: Oxford University Press 2016
Ämnen:
Original Research
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830417/
https://ncbi.nlm.nih.gov/pubmed/26895772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv498
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk